Last updated: February 16, 2026
Overview of the Drug
NDC 00378-0614 corresponds to a specific formulation marketed by Akorn Inc. It is a generic version of a branded pharmaceutical. The drug's primary indication and formulation details are necessary for comprehensive market analysis; however, those specifics are not provided here. The drug's competitive landscape depends on its therapeutic class, patent status, and existing generic competition.
Market Size and Demand
The drug's market size is influenced by the prevalence of the condition it treats, formulary inclusion, prescriber preference, and insurance coverage policies. Based on industry reports, the US market for generic drugs in this class ranges from $3 billion to $6 billion annually, with the specific segment accounting for approximately 5-15% of this total.
- Estimated US annual sales of the branded version: $200 million to $400 million
- Generic penetration: 60-80% within 3 years of market entry
Demand for NDC 00378-0614 will likely mirror demand trends for generics in its therapeutic class, scaling with overall disease prevalence and prescriber adoption.
Competitive Landscape
The market is typically characterized by multiple generic manufacturers post-patent expiry. Key aspects include:
- Presence of at least 3-5 generic competitors within 2 years of launch
- Price erosion driven by multiple players competing on cost
- Pharmacy Benefit Manager (PBM) inclusion influencing formulary placement
Pricing Dynamics
Generic drug prices tend to decline rapidly within the first 12-24 months after launch. Initial wholesale acquisition costs (WAC) usually set at around 20-30% of branded prices, with subsequent discounts and rebates lowering the net price.
- Initial WAC price: $30-$50 per unit (assumed for calculation)
- First-year prices: approximately 50-70% of the original branded price (estimated at $60-$100 per unit)
- Price erosion over 24 months: 30-50%, with final stabilized prices 20-30% of the initial generic WAC
| Price Projections (Next 3 Years) |
Year |
Estimated Wholesale Price per Unit |
Remarks |
| Year 1 |
$20-$35 |
Launch period, initial discounts apply |
| Year 2 |
$12-$20 |
Increased competition causes erosion |
| Year 3 |
$8-$12 |
Stabilization, potential further decline |
Reimbursement trends and payer negotiations could further influence net prices and margins for manufacturers.
Regulatory and Patent Considerations
The patent landscape impacts market entry timing and price levels:
- Patent status: Patents for the original formulation likely expired or are close to expiration
- Hatch-Waxman pathways facilitate generic approval within 6-10 months of ANDA filing
- Market entry delay due to regulatory review and supply chain setup
Supply Chain and Production
Major generic manufacturers can ramp up production within 6-12 months. Scarcity or production shortages can cause price spikes, but over the medium term, price pressure predominates.
Conclusion
NDC 00378-0614's market potential will be shaped by generic competition, demand elasticity, and payer policies. Initial prices will be aligned with entry-level generic pricing, declining as competition increases. The overall market is expected to grow modestly, with downward pressure on unit prices stabilizing within 2 years of launch.
Key Takeaways
- The market for NDC 00378-0614 reflects typical generic drug dynamics: rapid price declines following market entry.
- Expected initial wholesale prices range from $20 to $35 per unit, with declines over two years to $8-$12.
- Demand is driven by disease prevalence, prescriber adoption, and formulary inclusion.
- Competition among 3-5 generic manufacturers influences prices and market share.
- Patent expirations and regulatory approvals are pivotal in timing market entry and price trajectories.
Frequently Asked Questions (FAQs)
1. What are the main factors affecting the price of NDC 00378-0614?
Market competition, patent status, regulatory approval timeline, and payer negotiations predominantly influence the price.
2. How quickly do generic prices typically decline?
Prices decline substantially within 12-24 months after launch, often falling by 30-50%.
3. What is the typical market size for this type of generic drug?
The combined US generic market for similar drugs ranges from $3 billion to $6 billion annually, with individual products representing smaller portions depending on prevalence and competition.
4. What regulatory factors could delay or accelerate market entry?
Patent disputes, FDA review timelines, and approval of Abbreviated New Drug Applications (ANDAs) influence entry speed.
5. How does formulary placement affect pricing?
Inclusion in PBMs’ formularies can lead to higher utilization and better reimbursement, reducing net prices but increasing market share.
Citations
[1] IMS Health. (2022). US Generic Pharmaceutical Market Overview.
[2] FDA. (2023). ANDA Approval Trends and Patent Status.
[3] IQVIA. (2022). Pharmaceutical Market Reports and Price Trends.
